In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback